Clinical trials: Rosacea
Rosacea
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT01318733
- Testing
- CD07805/47 gel 0.5%
- Where
- 27 sites in United States
- Volunteers
- 449 people
- Sponsor
- Galderma R&D
Rosacea, Wrinkles
Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea
This study is designed to evaluate the efficacy and safety of the Luxe™ device for use in wrinkle and rosacea treatment. Up to 60 subjects will treat their periorbital and cheek areas daily for 4 weeks and then twice a week for…
- Trial name
- NCT01618864
- Testing
- Luxe
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Acne Rosacea
A Pilot Study on the Use of Seysara for Rosacea
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult…
- Trial name
- NCT04555525
- Testing
- sarecycline, Centrum Adult Multivitamin
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation
Rosacea
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576847
- Testing
- Omiganan
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Rosacea
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product…
- Trial name
- NCT03954444
- Testing
- Oxymetazoline Hydrochloride, Rhofade Cream, 1%
- Where
- United States
- Volunteers
- 1,105 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Rosacea
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
- Trial name
- NCT03590366
- Testing
- B244, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- AOBiome LLC
Port-Wine Stain, Rosacea
Skin Imaging to Inform Laser Treatments
The purpose of this study is to obtain information (such as lesion depth, depth of the most superficial part of the lesion, and the size and density of blood vessels) with the assistance of an imaging device, and use this…
- Conditions
- Port-Wine Stain, Rosacea, Telangiectasia, Angioma
- Trial name
- NCT04336163
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Rosacea
Rosacea and Ivermectin
The primary hypothesis is that weekly digital interactions and routine measurement of Transepidermal Water Loss (TEWL) rates and Subcutaneous hydration levels will promote patient adherence to maintenance ivermectin therapy and…
- Trial name
- NCT04275999
- Testing
- ivermectin, digital interaction, GPSkin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Acne Rosacea
Effects of PRK 124 Lotion in Acne Rosacea
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial…
- Trial name
- NCT00580723
- Testing
- PRK 124
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Irvine
Rosacea
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on the skin) in rosacea.
- Trial name
- NCT02806414
- Testing
- Ivermectin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Diego
Rosacea
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
- Trial name
- MUSE (NCT02637232)
- Testing
- Mirvaso® / Onreltea TM
- Where
- Canada
- Volunteers
- 301 people
- Sponsor
- Galderma R&D
Rosacea, Erythema
Patient-Reported Outcome Of Facial Erythema (PROOF)
The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness).
- Trial name
- PROOF (NCT01885000)
- Testing
- Brimonidine tartrate was applied cutaneously once daily for 8 days., Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.
- Where
- 14 sites in Germany, Sweden and 1 more
- Volunteers
- 92 people
- Sponsor
- Galderma R&D
Rosacea, Erythema
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
the study will measure the decrease in redness on the face of rosacea subjects
- Trial name
- NCT03352323
- Testing
- Oxymetazoline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Padagis LLC
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
Atralin Gel for the Treatment of Rosacea
Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels.
- Trial name
- NCT01125930
- Testing
- vehicle gel, Atralin gel
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Lisa E. Maier
Rosacea
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.
- Trial name
- NCT02828241
- Testing
- DFD-04 Ointment
- Where
- 8 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Dr. Reddy's Laboratories Limited